Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB

Last data update: Jul 05, 2022. (Total: 48041 Documents since 2012)
   dataset      
Filtered By:

Previous    

Records 1 - 30 (of 46 Records)

Next

Query Trace: Prostate cancer[original query]>>Evidence Synthesis [Product Type]
Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer.
Zhang Wensheng et al. Cancer informatics 2022 2111769351221087046
Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review.
Sushentsev Nikita et al. Insights into imaging 2022 13(1) 59
Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
McHugh Jana et al. British journal of cancer 2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
Palicelli Andrea et al. International journal of molecular sciences 2021 22(22)
Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Shi Zhuqing et al. The Prostate 2021
Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review.
Bandala-Jacques Antonio et al. JMIR cancer 2021 7(3) e30430
Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review.
Degeling Koen et al. European urology open science 2021 2777-87
Artificial Intelligence Compared to Radiologists for the Initial Diagnosis of Prostate Cancer on Magnetic Resonance Imaging: A Systematic Review and Recommendations for Future Studies.
Syer Tom et al. Cancers 2021 13(13)
Radiomic and Genomic Machine Learning Method Performance for Prostate Cancer Diagnosis: Systematic Literature Review.
Castaldo Rossana et al. Journal of medical Internet research 2021 23(4) e22394
Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Su Dan et al. Frontiers in pharmacology 2020 11610601
First-degree family history of prostate cancer is associated the risk of breast cancer and ovarian cancer.
Zheng QiongFei et al. Medicine 2021 Jan 100(4) e23816
A Systematic Review of Artificial Intelligence in Prostate Cancer.
Van Booven Derek J et al. Research and reports in urology 2021 1331-39
DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
Armstrong Nigel et al. Future oncology (London, England) 2020 Dec
Deep Learning in Radiation Oncology Treatment Planning for Prostate Cancer: A Systematic Review.
Almeida Gonçalo et al. Journal of medical systems 2020 Aug 44(10) 179
Automated Classification of Significant Prostate Cancer on MRI: A Systematic Review on the Performance of Machine Learning Applications.
T Jose M Castillo et al. Cancers 2020 Jun 12(6)
Mainstream consent programs for genetic counseling in cancer patients: A systematic review.
Scheinberg Tahlia et al. Asia-Pacific journal of clinical oncology 2020 Apr
Prognostic value of the SPOP mutant genomic subclass in prostate cancer.
Shoag Jonathan et al. Urologic oncology 2020 Mar
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender Tom et al. PLoS medicine 2019 Dec 16(12) e1002998
Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik Ghadeer et al. Journal of the National Comprehensive Cancer Network : JNCCN 2018 16(11) 1340-1351
CLINGEN Actionability Report for Acute Intermittent Porphyria - HMBS
ClinGen Actionability Working Group
CLINGEN Actionability Report for Hereditary Breast and Ovarian Cancer- BRCA1, BRCA2
ClinGen Actionability Working Group
CLINGEN Actionability Report for Lynch Syndrome - MLH1, MSH2, MSH6, PMS2, EPCAM
ClinGen Actionability Working Group
Surveillance after prostate focal therapy.
Tay Kae Jack et al. World journal of urology 2019 Mar 37(3) 397-407
Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
Lee Siang Ing et al. Journal of community genetics 2019 May
Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.
Fine Noam David et al. BJU international 2019 May
What Is the Effectiveness of Patient Decision Aids for Cancer-Related Decisions? A Systematic Review Subanalysis.
McAlpine Kristen et al. JCO clinical cancer informatics 2018 Dec (2) 1-13
Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
Chang Eric M et al. Urology 2018 Dec
Promise and Implementation of Proteomic Prostate Cancer Biomarkers.
Latosinska Agnieszka et al. Diagnostics (Basel, Switzerland) 2018 Aug 8(3)
NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: © NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
et al. BJU international 2018 Aug 122(2) 173-180
Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome.
Huang Dora et al. Bladder cancer (Amsterdam, Netherlands) 2018 Jul 4(3) 261-268
TOP